Akero Therapeutics, Inc.
AKRO
Kedudukan dalam Saham
#3734
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Harga Saham
$54.65
Disegerakkan terakhir: 2025-12-09
Modal Pasaran
$4.50B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
1.37%
Negara
US
Perdagangan Akero Therapeutics, Inc. (AKRO)
Kategori
Healthcare
Pendapatan untuk Akero Therapeutics, Inc. (AKRO)
Pendapatan pada Sep 2025 TTM: $-292.82M
Menurut laporan kewangan terkini Akero Therapeutics, Inc., pendapatan semasa syarikat ialah $-292.82M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-151.76M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-112.03M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Akero Therapeutics, Inc. dari 2017 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-292.82M | 16.17% |
| 2024 | $-252.06M | 66.09% |
| 2023 | $-151.76M | 35.46% |
| 2022 | $-112.03M | 11.17% |
| 2021 | $-100.78M | 27.23% |
| 2020 | $-79.21M | 81.02% |
| 2019 | $-43.76M | -46.45% |
| 2018 | $-81.71M | 1,690.40% |
| 2017 | $-4.56M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -1,901.41% |
US
|
|
| $-3.09B | 954.23% |
US
|
|
| $-4.02B | 1,271.56% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -766.16% |
NL
|
